DLL3 and small cell lung carcinoma: Rovalpituzumab tesirine (SC16LD6.5), an antibody‐drug conjugate targeting DLL3, has shown promising results in phase I studies against SCLC and large‐cell NE tumours, demonstrating encouraging single‐agent anti‐tumour activity and a manageable safety profile.